Singapore, 4 June 2009 – SPRING Singapore today announced that the second batch
of technology start-ups has won the second competitive grant under the Technology
Enterprise Commercialisation Scheme (TECS). A group of four portfolio companies
under Exploit Technologies, namely, Curiox Biosystems Pte Ltd, D-SIMLAB
Technologies Pte Ltd, Niometrics Pte Ltd and SG Molecular Diagnostics Pte Ltd, were
each awarded up to S$500,000 under TECS for their Proof-Of-Value Projects. There
were 13 winners in the Proof-Of-Value category.
TECS is a competitive grant and evaluated by investment professionals and industry
leaders. Only the strongest proposals with the best potential commercial outcome
are funded. The second batch of winners was evaluated on the commercial
potential, scientific and technical strengths, cost-effectiveness and impact of their
projects. A total of 21 new winners were selected from 220 submissions. Of the 21
start-ups, eight of them involved projects at the Proof-of-Concept (POC) stage, while
the remaining 13 were at the Proof-of-Value (POV) stage.
Commenting on the successful feat by Exploit Technologies’ portfolio companies, Mr
Boon Swan Foo, Executive Chairman of Exploit Technologies said, “To clinch the TECS
Award, after competing against more than 200 applicants, is already an
endorsement of these companies’ technical strengths and marketing and
development capabilities; to have four companies that made the mark, out of pool
of only 13 winners, is a strong testimony to A*STAR technologies and Exploit
Technologies’ efforts in nurturing these companies.
“Exploit Technologies has worked very closely with these four teams in the early
days of their business all the way through the TECS application. Experienced teams,
with extensive industry and start-up experience, have helped to shape the start-ups’
business plans, advise them on the product development roadmaps, open up doors
to business leads, mentor them on the various aspects of starting a business, find
funding through venture capitalists and angel investors, as well as prepare the
founders for elevated pitches. We believe that in helping A*STAR’s start-ups to
secure TECS Grant and other sources of funding, Exploit Technologies is developing a
multi-pathway approach to commercialisation. This will go a long way in bringing to
the market more of such promising technologies and companies.”
The founders of all four companies were either researchers with the Singapore
Agency for Science, Technology and Research’s (A*STAR) research institutes or have
leveraged A*STAR technologies in their businesses. Curiox Biosystems Pte Ltd was
spun off in 2007 from A*STAR Institute of Bioengineering Nanotechnology (IBN), DSIMLAB
Technologies Pte Ltd in 2006 from Singapore Institute of Manufacturing
Technology (SIMTech) and Niometrics Pte Ltd is a potential spin-off from the
Institute for Infocomm Research (I2R). SG Molecular Diagnostics Pte Ltd took a
licence from Exploit Technologies